Orchid Pharmaceuticals released the semi -annual report of 2022, achieving operating income of 33.7 million yuan

On August 31, Lanhua Pharmaceutical (Code: 870936.NQ) released the performance report of the 2022 Half -Annual Report.

From January 1, 2022-June 30, 2022, the company realized operating income of 33.7 million yuan, an increase of 10.23%year-on-year, net loss was 18.0476 million yuan, and the losses expanded by 3.87%year-on-year. The basic earnings per share were -0.1805 yuan.

The company's industry is chemical pharmaceutical.

During the company's reporting period, the total assets at the end of the period were 245 million yuan, the operating profit was -19.760 million yuan, the accounts receivable were 25.719 million yuan, and the net cash flow generated by operating activities was -7.2231 million yuan.The cash was 34.2774 million yuan.

Lanhua Pharmaceutical, the company's full name is Shanzhe Huaxi Pharmaceutical Co., Ltd., was established on February 13, 1998. The current general manager Zhao Jianzhong, the main business is the research and development, production and sales of chronic diseases such as cardiovascular and cerebrovascular diseases.

- END -